- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
- 10-K Annual report
- 3.1 Amended and Restated Certificate of Incorporation of the Registrant, As Amended
- 3.2 Amended and Restated Bylaws of the Registrant, As Amended
- 4.3 Warrant to Purchase Stock Agreement, Dated July 17, 2007
- 4.4 Amendment No. 1 to Warrant to Purchase Stock Agreement, Dated February 19, 2009
- 4.5 Warrant to Purchase Stock Agreement, Dated August 19, 2008
- 4.6 Amendment No. 1 to Warrant to Purchase Stock Agreement, Dated February 19, 2009
- 4.7 Warrant to Purchase Stock Agreement, Dated October 10, 2008
- 4.8 Amendment No. 1 to Warrant to Purchase Stock Agreement, Dated February 19, 2009
- 4.9 Warrant to Purchase Stock Agreement, Dated October 10, 2008
- 4.10 Amendment No. 1 to Warrant to Purchase Stock Agreement, Dated February 19, 2009
- 4.11 Warrant to Purchase Stock Agreement, Dated October 10, 2008
- 4.12 Amendment No. 1 to Warrant to Purchase Stock Agreement, Dated February 19, 2009
- 4.13 Warrant to Purchase Stock Agreement, Dated October 10, 2008
- 4.14 Amendment No. 1 to Warrant to Purchase Stock Agreement, Dated February 19, 2009
- 4.15 Warrant to Purchase Stock Agreement, Dated October 10, 2008
- 4.16 Amendment No. 1 to Warrant to Purchase Stock Agreement, Dated February 19, 2009
- 4.17 Warrant to Purchase Stock Agreement, Dated October 10, 2008
- 4.18 Amendment No. 1 to Warrant to Purchase Stock Agreement, Dated February 19, 2009
- 10.9 Lease, Dated February 8, 2008
- 10.10 Loan and Security Agreement, Dated July 17, 2007
- 10.11 First Amendment to Loan and Security Agreement, Dated January 21, 2009
- 10.12 Second Amendment to Loan and Security Agreement, Dated March 23, 2009
- 10.13 Note and Warrant Purchase Agreement, Dated September 24, 2008
- 10.14 Amendment to Note and Warrant Purchase Agreement, Dated October 10, 2008
- 10.34 Arca Biopharma, Inc. 2004 Equity Incentive Plan
- 10.35 Arca Biopharma, Inc. 2004 Equity Incentive Plan
- 10.36 Arca Biopharma, Inc. 2004 Equity Incentive Plan
- 10.37 Arca Biopharma, Inc. 2004 Equity Incentive Plan
- 10.38 Arca Biopharma, Inc. 2004 Equity Incentive Plan
- 10.43 Amended and Restated Employment and Retention Agreement, Dated June 4, 2008
- 10.44 Amended and Restated Employment and Retention Agreement, Dated July 7, 2008
- 10.45 Amended and Restated Employment Agreement, Dated June 12, 2008
- 10.46 Assignment and Assumption Agreement, Dated January 26, 2009
- 10.47 Assignment and Assumption Agreement, Dated January 26, 2009
- 10.48 Assignment and Assumption Agreement, Dated January 26, 2009
- 10.50 Employment Agreement, Dated February 24, 2009
- 10.51 Employment Agreement, Dated February 23, 2009
- 10.52 Indemnity Agreement
- 21.1 Subsidiaries of Arca Biopharma, Inc. As of March 24, 2009
- 23.1 Consent of Ernst & Young LLP, Independent Registered Public Accounting Firm
- 31.1 Certification of Chief Executive Officer
- 31.2 Certification of Chief Financial Officer
- 32.1 Certification of Chief Executive Officer and Chief Financial Officer
Exhibit 4.4
AMENDMENT NO. 1 TO WARRANT
TO
PURCHASE STOCK
THIS AMENDMENT NO. 1 TO WARRANT TO PURCHASE STOCK (this “Amendment”) is entered into as of the 19th day of February 2009, by and between ARCA biopharma, Inc., a Delaware corporation (f/k/a Nuvelo, Inc.) and SVB Financial Group.
Recitals
A. The Holder was previously issued a Warrant to Purchase Stock dated as of July 17, 2007 (the “Warrant”). Capitalized terms used in this Amendment, but not otherwise defined in this Amendment, shall have the meanings assigned to them in the Warrant.
B. Dawn Acquisition Sub, Inc., a Delaware corporation and wholly-owned subsidiary of ARCA biopharma, Inc., a Delaware corporation (f/k/a Nuvelo, Inc.), was merged with and into ARCA biopharma Colorado, Inc., a Delaware corporation (f/k/a ARCA biopharma, Inc. and ARCA Discovery, Inc.) (the “Merger”).
C. The Holder and ARCA biopharma, Inc., a Delaware corporation (f/k/a Nuvelo, Inc.) desire to amend the Warrant to reflect the closing of the Merger, the exchange of the common stock of the Company (as defined below) for the common stock of ARCA biopharma Colorado, Inc., a Delaware corporation (f/k/a ARCA biopharma, Inc. and ARCA Discovery, Inc.) and assumption of the Warrant as required by Section 1.6.2(d) of the Warrant in connection with the closing of the Merger.
Amendments
1. The Warrant Price shall be $14.61 per share, subject to adjustment after the date of this Amendment in accordance with the terms of the Warrant.
2. The Number of Shares shall be 6,475, subject to adjustment after the date of this Amendment in accordance with the terms of the Warrant.
3. The Class of Stock shall be the common stock, $0.001 par value per share, of the Company.
4. The Company shall be ARCA biopharma, Inc., a Delaware corporation (f/k/a Nuvelo, Inc.).
5. Except for revisions expressly set forth in this Amendment, the parties hereby ratify and confirm the terms of the Warrant in their entirety.
IN WITNESS WHEREOF, the undersigned have executed this Amendment to be effective as of the date first set forth above.
Company: | Holder: | |||||||
ARCA BIOPHARMA, INC. | SVB FINANCIAL GROUP | |||||||
By: | /s/ Christopher D. Ozeroff | By: | /s/ Norman Cutler | |||||
Christopher D. Ozeroff, Executive Vice | Print Name: | Norman Cutler | ||||||
of Business Development and General Counsel | Title: | Derivatives Manager |